Boehringer Ingelheim社、Genedata Selectorの利用拡大：
Genedata Selector deployed to streamline complex cell line development processes
November 7, 2019
Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced an expansion of its collaboration with Boehringer Ingelheim, a research-driven pharmaceutical company, to digitalize and automate complex cell line development processes. As part of this collaboration, Genedata Selector® has been deployed to support the application of next generation sequencing (NGS) in cell line engineering, clone selection and adventitious agent detection workflows.
Many biopharma companies, like Boehringer Ingelheim, are using NGS-based approaches throughout bioprocess development to speed up workflows and create significant cost savings. Genedata Selector harmonizes and automates these NGS-based workflows by providing an integrated data management and analysis platform. Genedata Selector offers all the features required for deployment into regulatory environments in downstream biologics manufacturing.
The centralized approach to global data management provided by Genedata Selector facilitates collaboration among research groups and sites and reduces error-prone exchange of data files. With an easy-to-use interface and enterprise-wide access to experimental data in one secure system, Genedata Selector enables biopharma companies to increase the efficiency of their decision-making processes. For specific applications, such as NGS-based detection of adventitious agents, Genedata Selector also creates the opportunity for biopharma R&D organizations to become independent of external service providers and gain full control of data, resulting in tremendous savings in time and money.
“We are very excited about our partnership with Boehringer Ingelheim, an innovative leader in the biopharma industry,” said Othmar Pfannes, Ph.D., CEO of Genedata. “Genedata is committed to supporting our customers looking to automate and digitalize their bioproduction processes by providing the most advanced and innovative technologies for organizations to maximize their return.”